Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies

The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners

Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch

Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)

Regeneron completes purchase of Sanofi's stake in Libtayo

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions

Nykode Therapeutics enters multi-target license and collaboration agreement with Regeneron

The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease

Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar

Biocon Biologics strikes deal to sell its version of the eye drug Aflibercept worldwide

All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed

EMA backs Eylea 8 mg for retinal vein occlusion

The positive CHMP opinion is supported by results from the Phase III QUASAR trial